UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K10-K/A

For The Fiscal Year Ended December 31, 20182020

or

For the transition period from _______________ to _______________

Commission File Number 333-208083

DSwiss, Inc.

(Exact name of registrant issuer as specified in its charter)

Unit 18-11, 18-12 & 18-01, Tower A, Vertical Business Suite,

Avenue 3, Bangsar South, No.8Jalan Kerinchi, 59200, Kuala Lumpur Malaysia., Malaysia.

(Address of principal executive offices, including zip code)

Registrant’s phone number, including area code(603)2770-4032

Securities registered pursuant to Section 12(b) of the Securities Exchange Act:None

Securities registered pursuant to Section 12(g) of the Securities Exchange Act:None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes [  ] ☐ No [X] ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes [  ] ☐ No [X] ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 9090 days.

Yes [X] ☒ No [  ]☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES [  ] NO [X]☐ No ☒

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [  ]☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company”in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [  ]☐ Accelerated Filer [  ] ☐ Non-accelerated Filer [  ] ☐ Smaller reporting company [X]☒ Emerging growth company [X]☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]☐

IndicateIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]☐ No [X]☒

The aggregate market value of the Company’s common stock held by non-affiliates computed by reference to the closing bid price of the Company’s common stock, as of the last business day of the registrant’s most recently completed second fiscal quarter:

Not Applicable

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Not Applicable

APPLICABLE ONLY TO CORPORATE REGISTRANTS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

0

EXPLANATORY NOTE

This Amendment No. 1 (“Amendment No. 1”) to the Annual Report on Form 10-K of DSwiss Inc., (the “Company”) for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2021 (the “2020 Annual Report”), is being filed to replace the Report of Independent Registered Public Accounting Firm included in the Form 10-K with an additional paragraph in the Report.

Except as described in this Explanatory Note, this Amendment does not modify, amend, or update any of the financial information or any other information set forth in the Form 10-K.

DSwiss, Inc.

FORM 10-K

For the Fiscal Year Ended December 31, 20182020

Index

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements. These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:

This report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Defined Terms

Except as otherwise indicated by the context, references in this Report to:

PART I

ITEM 1. BUSINESS

Corporate History

DSwiss, Inc., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on May 28, 2015.

DSwiss, Inc. operates through its wholly ownedwholly-owned subsidiary, DSwiss Holding Limited, a Company organized under the laws of Seychelles.

The principal activity of the Company and its subsidiaries is to supply high-quality health and beauty products, including beverages to assist in weight management, anti-aging products, and immune system products designed to improve the overall health system in our body.

We have historicallycurrently conducted our business through DSwiss Sdn. Bhd., a private limited liability company, incorporated in Malaysia. DSwiss Holding Limited, incorporated in Seychelles is an investment holding company with 100% equity interest in DSwiss (HK) Limited, a company incorporated in Hong Kong, which subsequent hold 100% equity interest in DSwiss Sdn. Bhd. We have invested in DSwiss Biotech Sdn. Bhd., a Company incorporated in Malaysia and owned a 40% equity interest. We have invested in DS Asia Co., Ltd, incorporated in Thailand, and owned 49% equity interest. The Company has incorporated DSwiss International Trading (Shenzhen) Limited in China, with a 100% equity interest on June 21, 2016. On November 9, 2020, DSwiss International Trading (Shenzhen) Limited has deregistered.

The Company, through its subsidiaries and its variable interest entities (“VIEs”), mainly supplies high quality beauty products. Details of the Company’s subsidiaries:

(1)Based on the contractual arrangements between the Company and other investors, the Company has the power to direct the relevant activities of these entities unilaterally, and hence the Company has control over these entities.

Business Overview

DSwiss is a premier biotech-nutraceutical company, supplying high-quality health and beauty products, including beverages to assist in weight management, anti-aging creams, and products designed to improve the overall health system in our body.bodies.

Since our establishment, our growth has been tremendous in Malaysia. From a mere selection of two (2) products, the company had expanded to eight (8)twenty-three (23) products by 2014.in 2020. With the strong leadership of our company’s Chief Executive Officer; Vincent Leong, our products are now consumed around the world, such as Malaysia, Singapore, Indonesia, Hong Kong, Taiwan, Macau, and China. To date, we had expanded across ASEANAsia regions through the support of our distributors and determined to expand our geographical presence to markets that we have yet to explore.

At DSwiss, research and development isare an ongoing effort whose purpose is to ensure our products on the forefront of quality and effectiveness. Equipped with state of the artstate-of-the-art machinery, our innovative research and development team are constantly exploring on new development and product lines that will enable us to provide the highest quality standard and remain competitive in the industry. In 2020, DSwiss has utilized food-grade bioflavonoids technology in its sanitiser product series and has helped address the risk of a lack of sanitiser products in Malaysia amid the coronavirus pandemic. With the team’s enormous efforts on product research and development, DSwiss has also successfully developed the functional Omega oil blend, mineral supplements such as calcium, magnesium and iron and antibacterial skincare product series. DSwiss is actively embarking on its journey to continue excel in functional food industry and expand into health supplement industry.

DSwiss’s products are certified and approved by the Ministry of Health (“MOH”) Malaysia. Due to the stringent requirements from MOH Malaysia, we strive to upkeep the highest possible standard in our products to provide assurance and continuous commitment to providing quality products. In 2020, DSwiss has fulfilled its last year future plan and ventured to supplying medical consumables in order to reduce the risk of a global shortage amid the coronavirus pandemic.

We recognize the growing trendTalent Development in Product Research and Development

The company hired food science professional, herbal science professional and biochemist professional as our product specialists to involve in developing new product research and development. Such development will require clinical studies, market research and testing of social mediaphysical products for overall effectiveness, and because of that, the management had decided to place a higher priority in social media for our marketing strategy. Coupledcomply with the extensive networks we had built sinceMinistry of Health Malaysia & JAKIM Halal standards. Currently, the company is undergoing research on the benefit of functional foods enhancing our inception, the nature of our job has become easierhuman body immune system, eye health, skin health, anticancer, brain development and efficient to reach out to our clients. But, perhaps the most imperative to our success is the ability to connect with our customers and receive their feedback directly. From the feedback we received,skin regeneration.

Currently, we are able to understand betterfulfilling last year future plan as in Talent Development, product research and development, and providing Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services into functional food and beauty product of our customer’s demandwhich is currently under research and make further improvements. As a result, our customers’ base has been growing exponentiallydevelopment with Malaysia biotech and resulted in a robust brand image of our company.

Moving forward, we plan to form certain alliances and business partnerships with few selected local companies from various countries. We strongly believe a healthy business relationship is vital for one’s business expansion, and more importantly; growth. While DSwiss has always been focused on pursuing operations within ASEAN, we certainly hope to expand our brand across the world in the future.

At the same time, we also expanded to globally recognised Turnkey Private Label Manufacturing Services for nutraceutical, skin care, personal care, eyecare and equipment OEM/ODM products.research professionals. Our professionals manage from custom formulation of scientifically-proven and naturally-effective, sourcing raw materials, production, quality control, stability and safety test, clinical testing by third-party labs, packaging and shipping including import and export, all licenses needed so customer can concentrate on what they should do. In 2020, with our experience and expertise, we have successfully expanded our client base in OEM/ODM services and developed products and Business-to-business (B2B) DNA genotyping private label services that exceed the clients’ expectation.

Moving forward, we plan to form certain alliances and business partnerships with a few selected local companies from various countries. We strongly believe a healthy business relationship is vital for one’s business expansion, and more importantly; growth. While DSwiss has always been focused on pursuing operations within Asia, we certainly hope to expand our brand across the world in the future.

Our Products

D’SwissDSwiss Coffee

DSwiss Coffee is a combination of Citrus Extract and eight other natural ingredients for digestive health. Apart from cleansing your digestive system,burning the fats, the drink provides a soothing and refreshing sensation..sensation.

It’s Helps:It helps to:

DSwiss Kiwi

Kiwi helps to strengthen the body’s immune system, improves skin complexion, reduces blood pressure and prevents heart disease and stroke. DSwiss Kiwi helps to reduce the risk of getting gastrointestinal diseases such as irritable stomach disorders and dermatitis.

It’s Helps:It helps to:

D’SwissDSwiss Triple Stem CellSC

D’Swiss

DSwiss Triple Stem CellsSC focuses on stem cell and consists of three (3) types of cell’s combination which includes Apple Stem Cells, BlueberriesArgan Stem Cells and MallowGrape Stem Cells.

Apple Stem Cells are extracted from the rare “Uttwiler Spatlauber” apples. It contains rich nutrients, protein, and amazing vitality of plant stem cells. It helps to protect and renew skin cells.

Blueberries contain powerful constituents by blocking Argan Stem Cells help maintain functions of dermis to provide elasticity to the detrimental sugar-protein reactions that occur duringskin. In order to maintain elasticity, healthy skin glycation.undergoes constant cell turnover, which renews and repairs the dermal connective tissue. It helps to rejuvenate skin cells and reduce wrinkles.

Mallow Grape Stem Cells areprotect the traditional medicine in Europeskin from chronological and it is extracted from marshmallow flower. light-induced aging, extending skin cells’ vitality and keeping the skin’s appearance young and beautiful longer. It helps improve the skin’s resistance.

It helps to moisturize and repair damaged skin cells.improve:

It’s Helps to Improve:

DSwiss Silk Mask

The mask is made by natural silk which contains a structure that is similar to human skin. DSwiss Silk Mask best suits for customers who have dry, damaged and sensitive skin. Silk contains 18 types of amino acids to moisturize the skin, strengthens the skin elasticity as well as repairs skin cells. Also, it brightens the skin tone and restores the skin health of users.

Unique Characteristics:

It’s Helps:

DSwiss Coffee Slimming Scrub

DSwiss Coffee Slimming Scrub is a natural body scrub containing fine uniform particles, mainly used to remove dirt withinon the skin layers, through a gentle friction with skin. It is also used to exfoliate the skin to remove dead skin, smoothen the skin and promote skin metabolism.

This is a physical method to remove dead skin layer, so one must be gentle in the course of action. It is recommended to use a moisturizer after exfoliating to nourish the skin.

The product can be divided toused as face scrub or body scrub. Alternatively, we can use this product to remove dead skin at the joint ofon our body.joints. The product also helps to eliminate excess fats and may apply to therapeutic use.

It’s Helps:

DSwiss Peppermint Slimming Gel

DSwiss Peppermint Slimming Gel is an effective cooling agent which brings a cooling and refreshing feeling to the body. Peppermint is one of a commonly used Chinese herb to reduce symptoms of influenza, sore throat, and even weight loss! It helps to provide the slimming effect of silhouette and soothing skin.

DSwiss Peppermint Slimming Gel contains ingredients such as The purified menthol (active thermo agent) to help activateingredient helps activating cellular micro-circulation. It is also formulated with avant-garde plant extract that aids in reducing stretch mark and scars.

It’s Helps:

DSwiss New Age Essence

For younger and healthy-looking skin.

The multi-action DSwiss New Age Essence delivers skin-loving nutrients to moisten, brighten and revive tired looking skin. It brings a youthful vitality to your delicate skin and convenient to be used at anytime, anywhere and whenever you need.

The key active ingredient of the product, RoyalEpigen P5 which inspired by epigenetic science, this peptide mimics royal jelly to maximize its positive effects on the skin. It is a new and biologically-active peptide that activates skin regeneration and glow. Scientists discovered that epigenetic modification may passed down from one generation to the next by the technology of epigenetic science.

Additionally, PhytoCellTec™ is the technology used to generate and cultivate the key active ingredients, Nunatak® stem cell and apple stem cell. PhytoCellTec™ has used the auto-repair function of plant stem cell to replicate a large number of new cells, and then continue to grow into stem cells. This stem cell is filled with regeneration growth factor and metabolic factor, which can enhance DNA repair and slow down aging process. This is one of the remarkable anti-aging discoveries for this century.

It helps to:

Additionally,

DSwiss Enlighten Essence (“EE”) Cream

Brightened, Flawless, Even- toned. This extraordinary Luminous White Cream is effective to cover skin imperfection, yet providing a natural look on skin throughout the day. It is a light and nourishing cream adapted to all skin types, to protect, conceal, and enlivens, dull looking complexions for a luminous complexion.

PhytoCellTec™ is the technology used to generate and cultivate the key active ingredients, Nunatak® stem cell and apple stem cell. PhytoCellTec™ has used the auto-repair function of plant stem cell to replicate a large number of new cells, and then continue to grow into stem cells. This stem cell is filled with regeneration growth factor and metabolic factor, which can enhance DNA repairing and slow down aging process. This is one of the remarkable anti-aging discoveries for this century.

It’s Helps:SuiSu Hand Purifier and Sanitiser

DSwiss Enlighten Essence (“EE”) Cream

Brightened, Flawless, Even- toned.

This extraordinary Luminous White CreamSuiSu Hand Purifier and Sanitiser is a powerful alcohol-free antibacterial hand sanitiser that is effective to coverin maintaining the hand hygiene, keeping the skin imperfection, yet providing a natural look on skin throughoutmoisturized, soft and protecting the day. It is a lighthands against germs and nourishing cream adapted to all skin types, to protect, conceal, and enlivens, dull looking complexions for a luminous complexion.

PhytoCellTec™ is theviruses. The food-grade bioflavonoid technology used was tested and proven to generatebe effective against common household bacteria, molds, fungi and cultivateeven coronavirus. This advanced and unique ingredient is certified by BioGro Organic New Zealand,

Australian Therapeutic Goods Administration, EcoCert Cosmos Natural, NASAA Organic and even FDA GRAS. Being chemical- free and non- toxic, the key active ingredients, Nunatak® stem cellproduct is safe and apple stem cell. PhytoCellTec™ has used the auto-repair function of plant stem cell to replicate a large number of new cells,harmless for kids and then continue to grow into stem cells. This stem cell is filled with regeneration growth factor and metabolic factor, which can enhance DNA repairing and slow down aging process. This is one of the remarkable anti-aging discoveries for this century.family.

It’s Helps:

DSwiss BioSpec

SuiSu Air Sanitiser

SuiSu Air Sanitiser maintains the surrounding air clean and fresh for a healthier living. It is ideal for cleaning surfaces and area that you come into contact with every day, such as door handles, kitchen bins, toilet areas, curtains, sofas, mattresses and most soft fabrics. The food-grade bioflavonoid technology used was tested and proven to be effective against common household bacteria, molds, fungi and even coronavirus. This advanced and unique ingredient is certified by BioGro Organic New Zealand, Australian Therapeutic Goods Administration, EcoCert Cosmos Natural, NASAA Organic and even FDA GRAS. Being chemical- free and non- toxic, the product is safe and harmless for children and pet.

SkinEra

Specially formulated to deliver unique 5-in-1 skin solutions: antibacterial, anti-inflammatory, antioxidant, epidermis repair and moisturizing. SkinEra is infused with the unique bioflavonoid technology, mangosteen skin extract and high purity essential oils, its premium quality delivers a sophisticated key to skin problems such as acne, pimples, atopic dermatitis, dry skin and even allergy rashes.

SensiBath

SensiBath is saturated with high moisturizing factor to replenish the moisture stripped from our everyday life activities and maintain the skin barrier moist and healthy through filaggrin boost. Its skin barrier strengthening ability is able to hydrate and relieve skin problems such as dry skin, atopic dermatitis, wrinkles and acne. The gentle formulation is hypoallergenic, dermatologically-tested and dedicated to provide a 24-hour long-lasting hydration and moisturization after single use, thus able to re-energize and regenerate skin cells for silky smooth skin.

Medical Consumables

DSwiss BioSpec

DSwiss BioSpec is the varieties of spectacles that consist of two (2) main partsa medical eye-wear which provides health benefits to our eyes.

(1) Frame

The main components of the DSwiss BioSpec frame are Negative Ions, Far Infra Ray, Nano Silver, and Germanium.

(2) Lens

The main components of DSwiss BioSpec lenses are UV 400 filters, Anti-blue Light, and Far Infrared.

Major Features:

Genmune-Pro

Genmune-Pro

Genmune-Pro is a pro- and pre-biotic product that helphelps to boost up the human’s immunity system through enhancing the colon’sdigestive health. In fact, 70% of our immune system resides in our gut. One of theIt is uniquely formulated with probiotic strains Bifidobacterium longum BB536, Lactobacillus rhamnosus GG, prebiotic used in the Genmune-Pro isgalacto-oligosaccharides and Wellmune® Baker’s Yeast Beta Glucan.

Wellmune® is a natural food, beverage and supplement ingredient which is clinically proven Genmune-Pro helps to help strengthen the immune system.

Wellmune® has been shown to help:

Wellmune® is:

Wellmune® has regulatory approval in major markets around the world, including GRAS statusreplenish beneficial bacteria in the U.S.gut to support digestive and novel food approval in Europe and China. With a focus on healthy immune system and its benefits, products containing Wellmune® are available inhealth.

Scientifically proven by more than 60 countries.

150 clinical studies, Bifidobacterium Longumlongum BB536

The probiotic, Bifidobacterium Longum BB536 used in Genmune-Pro is a kind of bacteria that is beneficial to the human body. It is commonly used in foods for bifidobacteria and has the effect of regulating intestinal health.

Strains from human origin can be maintained in our intestines for longer periods of time. By using lyophilization (freeze-drying) technology, these strains with high stability are in a sleep mode and only wake up when they enter our body. Therefore, it helps promote promotes intestinal health, supports a healthy immune system, relieves constipation and enhances bone strength.

It’s helps:Scientifically proven by more than 800 clinical studies, Lactobacillus rhamnosus GG promotes digestive health, protects against upper respiratory tract infections and cavities and improves skin condition.

Wellmune® is a proprietary baker’s yeast beta glucan. It uses a unique mechanism to boost immune system by priming the immune cells to kill foreign bacteria faster. Galacto-oligosaccharides stimulate the growth of probiotic bacteria and retard the growth of harmful bacteria.

It helps to:

GenCell Biotech New Age Essence

This GenCell Biotech New Age Essences is a convenient, ready-to-use multi-effect skin care product. It nourishes the skin with nutrients to moist, brighten and restore tired skin. To this end, it brings youthful vitality to your delicate skin.

The RoyalEpigen P5, is the main active ingredient of this product. It is a peptide that mimics royal jelly to maximize its positive effects on the skin. This inspiration comes from epigenetics. Scientists have found that epigenetic modification techniques can be passed on from generation to generation through epigenetic techniques. This new bioactive peptide activates our skin regeneration and luminescence.

Another technology is PhytoCellTec™, which is used to generate and cultivate two key active ingredients, Nunatak® Stem Cells and Apple Stem Cells. PhytoCellTec™ utilizes the automatic repair system of plant stem cells to replicate large numbers of new cells. These stem cells have enhanced the DNA repair and delay the aging process because they are filled with regenerative growth factors and metabolic factors. This technology is one of the most significant anti-aging discoveries of this century.

Furthermore, RedSnow® is the natural extract from Camellia Japonica flower which provide strong anti-oxidation efficacy. RedSnow® has the anti-inflammation effect and showed its anti-wrinkle effect by promoting the collagen boosting in our skin. With the RedSnow®, it helps to increase the collagen synthesis, and enhance our skin hydration with no significant evidence of primary irritation on human skin. RedSnow® is also specialized for anti-pollution where it presents a quite a good anti-aging activity in relation to a pollutant stress. It is also reasonable stability under heat and UV radiation.

It’s helps:

GenCell Biotech EE Cream

This unique Luminous White Cream contains ingredients effective for covering skin imperfections, and help the skin achieve a great natural look for all day long. Its texture is quite light, nourishing, and is compatible with all types of skin. It also has the protective and conceal effects that improves dull skin tone and brightens our skin tone.

Also, the key active ingredient of this product is the RoyalEpigen P5, a peptide that provide good skin benefits. This inspiration comes from epigenetics where it mimics the royal jelly to maximize its positive effects on the skin. According to scientists, epigenetic modification techniques can be passed on to the next generation through epigenetics techniques. This new bioactive peptide activates our skin through promotes regeneration cell. It also revive dull skin and make our skin look more radiant.

The PhytoCellTec™, this technology has become one of the biggest breakthroughs in the field of anti-aging. It forth putting the self-healing ability of the plant stem cells, to replicate and regenerate new cells in large quantities. These PhytoCellTec™ stem cells are filled with regenerative growth factors and metabolic factors. It’s can assist in strengthening the DNA repair and delay the aging process in human.

One of other main ingredients contained in Luminous White Cream is the Inca Inchi Oil. It comes from the cultivation of the Plukenetia Volubilis in the Amazon region of Peru. Inca Inchi Oil rich in omega-3, -6 and -9. It is the most abundant omega-3 (Ω3) oil in all known natural resources such as olive, sweet almond, evening primrose and etc. Inca fruit oil is effective for eliminating inflamed, swollen, dry and damaged cell tissue. It also contains high levels of antioxidants including vitamin A and vitamin E. Inca Inchi Oil helps to improve skin barrier function, protect the skin, maintain lipid balance, and improve the texture of the epidermis.

It’s helps:

GenCell Skin Care Travel Pack

An easy carry travel pack, the mini-sized GenCell Biotech New Age Essence and EE Cream is extremely convenient, light and suitable for travelers. Now everyone can replenish and rejuvenate the skin anytime, anywhere.

Our Equipment

DSwiss Quantum Magnetic Analyzer

In year 2017, DSwiss launched Quantum Magnetic Analyzer, an equipment that rapidly reads and analyze body energy field to test the health status and suggest recommendations. Simply by holding sensors in your palm, health data from multiple body systems will be collected and analysed within minutes.

The DSwiss Quantum Magnetic Analyzer offers new high-tech innovation to collect data from the magnetic field of human cells for scientific analysis. This provides the user with a guide to determining their health status and potential problematic areas with solution recommendations.

DSwiss Quantum Magnetic Analyzer provides more than 30 types of test analysis. A complete health screening will help you to assess your overall health and identify the risk factors for disease.

AI Skin Analyzer Machine

The intelligent facial camera is one of the recognized statistical instruments for facial skin image data. Capable of capturing high-definition facial images in RGB+UV+PL three-spectrum, it uses artificial intelligence (AI) algorithms to analyze skin features for the beauty industry. It also provides a data reference for tailored skincare solutions in the beauty industry.

By running the smart camera software in the tablet, the controller receives the tablet software command. This allows for change of the constant current source to control the corresponding LED light. The tablet is connected to the camera through the USB port to collect image analysis.

Major Functions:

It analyses the conditions of skin through different aspects:

Unique Characteristics:

International Turnkey Private Label Manufacturing Service

Our professionals manage from custom formulation of scientifically-proven and naturally-effective, sourcing raw materials, production, quality control, stability and safety test, clinical testing by third-party labs, packaging and shipping including import and export, all licenses needed so customer can concentrate on what they should do. We have export and import experience in dealing with both overseas and domestic customers.

Besides, we ventured into the genetic testing field and provide private label DNA screening service. The DNA analysis is performed at accredited laboratory with international recognized quality standards and protocols. The information processed is handled with utmost accuracy and trusted security in order to protect the privacy of users.

OEM/ODM Services Products

Yumeka Hair Shampoo and Conditioner

Yumeka Hair Shampoo and Conditoner are all- natural hair care products that serve 5R functions: Repair, Refresh, Restore, Reinforce and Revitalize. They are effective in reducing itchy scalp, dandruff and oil production as well as moisturize hair scalp and strengthening the hair roots, resulting in lustrous silky-smooth hair. The mild formulation in Yumeka makes it free of SLS, SLES, parabens, sillicone and thus user- friendly.

The key ingredient of this product, Cleomilk®, is a plant- based phytomilk that reduces moisure loss from skin, improves re-lipidation effect and reinforces the skin’s natural water storage. Multiple in-vivo tests conducted have shown that the long-chain polysaccharides will form a protective film on the skin to reduce trans-epidermal water loss. Then, the lamellar lipid matrix and natural moisturizing factors within our skin or scalp structure can be supported and reinforced well enough.

The microbiota on our hair lives a delicate balance and our daily activities might easily disturb it. The prebiotic in the product serves as a food supplement for the protective skin biota which cannot be digested by the harmful ones. It forms a protective anti-microbial shield against hostile organisms and important changes such as UV light, pollutants and cleansing products, promoting healthy hair growth and scalp.

Trademark

MasterLiv

MasterLiv is a unique formula that includes a blend of Turmeric Root, Milk Thistle, Chlorophyll, Selenium and Wheatgrass. It is formulated to help support liver health and the body’s vital detoxification processes. The blend of nutrients and plant extracts in MasterLiv protects the liver from free-radical damage, promotes cellular lifespan and supports optimal detox performance by empowering the liver’s capacity. By effectively aiding in removing the accumulated toxin in liver, it enhances the energy level and help combat tiredness. The formulation is free of preservative, drug ingredient, toxic chemical and hormone.

MasterHeart

MasterHeart is a combination of nutrients and plant extracts including Ganoderma lucidum, Panax ginseng, vitamin K2, goji berry and Kombu, designed to support the heart’s role in these processes and help maintain optimum heart health and smooth blood circulation for lower risk of developing coronary heart diseases. The unique natural formulation is free of stimulants, hence suitable for all ages and will not contribute to any side effects.

WellG

WellG is a synergistic combination of nutrients and powerful botanicals such as bitter melon extract, fulvic acid, chromium, ALA and L-arabinose, providing the important nutrients needed for the metabolism of sugar, and for energy production. This unique combination of ingredients naturally supports healthy blood sugar balance and energy metabolism, as well as cardiovascular and immune health, for overall well-being. The formulation is free of preservative, drug ingredient, toxic chemical and hormone.

DNA Microarray Genotyping

Genotyping detects small genetic differences that can lead to crucial changes in physical composition, including both physical differences that make someone special and pathological changes underlying disease. Our genotyping is using Asian Screening Array to yield better results and analyzing over 550 different genes. A comprehensive insight about nutrient needs, drug sensitivity, health risk, carrier status and many more is provided with more than 500k markers tested, over 100 alleles compared and above 300 actions suggested.

Trademark

The Company owned several trademark register under its subsidiaries in respective jurisdiction of which the subsidiary is operates.

Category	●	Registration Number		Trade Marks Logo		Ownership		Country		Date of Effective & DurationCambodia
Trademark	●	2014050439		[Class 30]		DSwiss Sdn Bhd		Malaysia		January 13, 2014 For 10 Years
Trademark	●	2014050437		[Class 3]		DSwiss Sdn Bhd		Malaysia		January 13, 2014 For 10 Years Singapore
Trademark	●	303538198China
	●	[Class 3] [Class 30] [Class 32]		DSwiss (HK) Limited		Hong Kong
	●	January 17, 2017 For 10 Years India
	●	Myanmar
	●	Vietnam
	●	EUIPO

Trademark		KH/67854/16		[Class 3]		DSwiss (HK) Limited		Cambodia		February 29, 2016 For 10 Years
Trademark		4/3643/2016		[Class 3]		DSwiss (HK) Limited		Myanmar		April 4, 2016 For 3 Years
Trademark		4/3644/2016		[Class 30]		DSwiss (HK) Limited		Myanmar		April 4, 2016 For 3 Years
Trademark		40201603915Q		[Class 3]		DSwiss (HK) Limited		Singapore		March 3, 2016 For 10 Years
Trademark		40201603916W		[Class 30]		DSwiss (HK) Limited		Singapore		March 3, 2016 For 10 Years
Trademark		18053593		[Class 32]		DSwiss (HK) Limited		PRC		November 21, 2016 For 10 Years

Future Plan

Marketing Campaign and Publicity Enhancement

The Company is actively seeking opportunity to increase the market share of beauty and health industry locally and overseas, of which requires continuous spending on marketing campaign primarily via social media and other online e-commerce platform which already in place currently to ensure the company product exposure and brand awareness.

Future marketing campaign and publicity enhancement will be conduct thru but not limited to following:

Campaign are customized based on the regions, countries, genders and cultures. Currently our products are available in China, Hong Kong, Malaysia, Thailand, Singapore, Taiwan and Indonesia.

Product Research and Development

The Company decided to allocate funds into developing new product lines that may be more appealing to other markets. Such development will require market research and testing of physical products for overall effectiveness, not to mention approval by respective regulatory bodies in the areas that such products will be sold in. Currently the Company is undergoing a research on the benefit of functional foods enhancing the function of human liver and lungs. The company also intended to conduct research and development on the benefits of RoyalEpigen P5 and Multi-Lamellar Emulsion (MLE) towards human skin, potentially launching a new skin care product.

Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM)

The Company intended to venture upstream by providing Original Equipment Manufacturing and Original Design Manufacturing services in aforementioned functioning food and beauty product of which is currently under research and development to Europe, U.S., Taiwan and Malaysia.

Human Resources and Talent Development

Taking into consideration of the aforementioned development, the company is well aware that with existing man powermanpower is far from sufficient to the materialization of future plan, thus spending on human resources and talent development is inevitable, including but not limited to internal admin and operation, sales and marketing, accounting and finance as well as top management.

Merger and Acquisition

The Company is actively seeking opportunity to merge and acquire potential target company to derive extraordinary synergies in multiple segments but limited to healthcare, bio-technology, beauty slimming and wellness, food science and related industries. The management believe that organic growth itself is incapable to copeof coping with the expectation of shareholders in the current dynamic business environment, thus via merger and acquisition the Company can create greater value to every stakeholder not limitinglimited to shareholders.

Marketing

We recognize the growing trend of social media and because of that, the management had decided to place a higher priority on social media for our marketing strategy. Coupled with the extensive networks we had built since our inception, the nature of our job has become easier and efficient to reach out to our clients. But, perhaps the most imperative to our success is the ability to connect with our customers and receive their feedback directly. From the feedback we received, we can understand our customer’s demands better and make further improvements. As a result, our customers’ base has been growing exponentially and resulted in a robust brand image of our company.

Competition

Competition

The beauty and healthcare industry is highly competitive, we might be in disadvantage competing with competitor who greater reserve or access to capital than we do to carry out operations and marketing efforts. We hope to maintain our competitive advantage by utilizing the experience, knowledge, and expertise of our current staff as well as offering exemplary our customer service.

Customers

For the year ended December 31, 2018,2020, the Company has generated $220,119$1,347,718 revenue from clients under the ordinary course of business of the Company. The revenue mainly represented OEM sales of Nutraceutical / Skincare and Medical Consumable Supplies to agent and direct sales to clients on social media.clients.

Employees

As of December 31, 2018,2020, the Company has twelve (12)six (6) full time employees including Mr. Leong Ming Chia who is our Chief Executive Officer, director, secretary and treasurer that works full time.

Currently, both of our directors all have the flexibility to work on our business up to 25 to 3060 hours per week, but are prepared to devote more time if necessary.

We do not presently have pension, health, annuity, insurance, stock options, profit sharing, or similar benefit plans; however, we may adopt plans in the future. There are presently no personal benefits available to our Officers, Directors or employees.

Government Regulation

We are subject to the laws and regulations of the jurisdictions in which we operate, which may include business licensing requirements, income taxes and payroll taxes. In general, the development and operation of our business is not subject to special regulatory and supervisory requirements.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 2. PROPERTIES

Our principal executive office is located at Unit 18-11, 18-12 & 18-01, Tower A, Vertical Business Suite, Avenue 3, Bangsar South, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia.

The loan in the principal amount of MYR80,000 (approximately $18,856) which the Company obtained from Public Bank Berhad in November 2016 to finance the acquisition of a motor vehicle, is no longer exist as of December 31, 2018 as the motor vehicle was being traded in during year 2018.

In July 2018, the Company obtained a new loan in the principal amount of MYR250,000 (approximately $60,479) from Public Bank Berhad, a financial institution in Malaysia, to finance the acquisition of a motor vehicle. The loan bears interest at the base lending rate less 2.38% per annum, is payable in 83 monthly instalments of MYR3,473 (approximately $840) each and a final monthly instalment of MYR3,391 (approximately $820) and matures in June 2025.

As of December 31, 2018,2020, the Company has an outstanding loan to be settle for aforementioned acquisition of motor vehicle of MYR234,867MYR170,138 (approximately $56,818)$42,194), of which MYR31,526MYR39,823 (approximately $7,627)$9,876) to be settled in 12 instalments in year 20192021 and MYR203,341MYR130,315 (approximately $49,191)$32,318) to be settlesettled in 6642 instalments after year 2019.2021.

Loan acquired for the acquisition of motor vehicle mentioned above are denominated in MYR, of which subjected to the fluctuation in reporting currency.

ITEM 3. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is currently quoted on the OTC Pink under the trading symbol “DQWS.”

Trading in stocks quoted on the OTC Pink is often thin and is characterized by wide fluctuations in trading prices due to many factors that may have little to do with a company’s operations or business prospects. We cannot assure you that there will be a market for our common stock in the future.

For the periods indicated, the following table sets forth the high and low bid prices per share of common stock based on inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

Holders

As of December 31, 2018,2020, we had 206,904,600 shares of our Common Stock par value, $.0001 issued and outstanding. There were 158411 beneficial owners of our Common Stock.

Transfer Agent and Registrar

The transfer agent for our capital stock is VStock Transfer, LLC, with an address at 18, Lafayette Place, Woodmere, New York 11598 and telephone number is +1 (212)828-843.

Penny Stock Regulations

The Securities and Exchange Commission has adopted regulations which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share. Our Common Stock, when and if a trading market develops, may fall within the definition of penny stock and be subject to rules that impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000, or annual incomes exceeding $200,000 individually, or $300,000, together with their spouse).

For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser’s prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Consequently, the “penny stock” rules may restrict the ability of broker-dealers to sell our Common Stock and may affect the ability of investors to sell their Common Stock in the secondary market.

In addition to the “penny stock” rules promulgated by the Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit the investors’ ability to buy and sell our stock.

Dividend Policy

Any future determination as to the declaration and payment of dividends on shares of our Common Stock will be made at the discretion of our board of directors out of funds legally available for such purpose. We are under no contractual obligations or restrictions to declare or pay dividends on our shares of Common Stock. In addition, we currently have no plans to pay such dividends. Our board of directors currently intends to retain all earnings for use in the business for the foreseeable future.

Equity Compensation Plan Information

Currently, there is no equity compensation plan in place.

Unregistered Sales of Equity Securities

Currently, there is no unregistered sales of equity securities.

Purchases of Equity Securities by the Registrant and Affiliated Purchasers

We have not repurchased any shares of our common stock during the fiscal year ended December 31, 2018.2020.

ITEM 6. SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and the notes to those financial statements appearing elsewhere in this Report.

Certain statements in this Report constitute forward-looking statements. These forward-looking statements include statements, which involve risks and uncertainties, regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategy, (c) anticipated trends in our industry, (d) our future financing plans, and (e) our anticipated needs for, and use of, working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plan,” “potential,” “project,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” or the negative of these words or other variations on these words or comparable terminology. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements.

The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Overview

DSwiss, Inc., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on May 28, 2015. DSwiss Holding Limited owns 100% of DSwiss (HK) Limited, a Hong Kong Company, which owns 100% of DSwiss Sdn Bhd, the operating Malaysia Company of which is described below. In 2016, DSwiss (HK) Limited invested in DSwiss Biotech Sdn Bhd, incorporated in Malaysia, and owned 40% equity interest. DSwiss (HK) Limited also invested in DS Asia Co., Ltd, incorporated in Thailand, and owned 49% equity interest. We have incorporated a new company namely DSwiss International Trading (Shenzhen) Limited in China, with 100% equity interest owned by DSwiss (HK) Limited. On November 9, 2020, DSwiss International Trading (Shenzhen) Limited was officially deregistered.

Our Company is a beauty supply company formed with the goal of supplying high quality beauty products directly to our clients. Our beauty supplies include, but are not limited to, beverages to assist in burning and reducing fat, anti-aging creams, and products designed to improve the overall health and physical appearance of our clients. Currently we supply our products in Malaysia, Singapore, Thailand, Indonesia, Hong Kong and China. However, we have intentions to expand to Myanmar, Macau, Vietnam and Cambodia, and subsequent to that we will make efforts to expand throughout the world a premier biotech-nutraceutical company, supplying high-quality health and beauty products, including beverages to assist in weight management, anti-aging creams, and products designed to improve the overall health system in our body.

At this time, we operate exclusively online through our website: http://www.dswissbeauty.com/

Our Company continuously strives to improve the already high standard of our goods and services through ongoing research and market development. We are going to penetrate into South East Asia markets through the recruitment of distributors and via the social media like Facebook and Instagram. We foresee to spend a substantial amount in marketing and advertising in the coming year. At DSwiss we are determined to bring new products to markets that we have not yet explored.

Products which meet the definition of a medicinal scopefunctional food and cosmetics related products need to be registered or notified with the Drug Control Authority (DCA), Ministry of Health Malaysia. Manufacturing, marketing, importation and the sale of unregistered products is a violation of the Drug Control Regulations and Cosmetics Act 1984 of Malaysia and enforcement action can be taken.

At DSwiss, research and development is an ongoing effort whose purpose is to ensure our products on the forefront of quality and effectiveness. Equipped with state of the art machinery, our innovative research and development team are constantly exploring on new development and product lines that will enable us to provide the highest quality standard and remain competitive in the industry.

DSwiss’s products are certified and approved by the Ministry of Health (“MOH”) Malaysia. Due to the stringent requirements from MOH Malaysia, we strive to upkeep the highest possible standard in our products to provide assurance and as a prove of our continuing commitment to providing quality products.

We always strive to offer products as high quality as possible, and hope that this assurance from an esteemed regulatory body will also serve to prove our continuing commitment to providing quality goods.

DSwiss have own brand Quantum Resonant Magnetic Analyzer which is DSwiss Quantum Resonant Magnetic Analyzer. DSwiss Quantum Resonant Magnetic Analyzer is a Hi-tech innovation project, which is related to medical, bio-informatics, electronic engineering, etc. It is based on quantum medical, and scientifically analyzes the human cell’s weak magnetic field collected by advanced electronic device. The analyzer can work out the customer’s health situation and main problem. According to the checking result, the analyzer can figure out the reasonable treatment recommendation. The quantum resonant magnetic analyzer is the individualized guide of comprehensive healthy consulting and updated healthy sciences, and its characteristics and advantages are comprehensive, non-invasive, practical, simple, quick, economical and easy to popularize. We can see DSwiss Quantum Resonant Magnetic Analyzer can help our customers to more concern about their health and skin condition.

Our expected growth is planned to occur primarily through the implementation of our social media marketing strategy. DSwiss already has a strong relationship with social media (eg. Facebook, Instagram and Wechat). The global presence social media has helped provide to us has been an invaluable resource, and as we continue to expand our business operations and spread our brand awareness, we intend to primarily utilize social media to reach our customers. The benefits of social media are countless, but perhaps the most imperative to our future success is our ability to connect with customers directly, to receive their feedback almost instantaneously. On that note, the feedback we have received from our clients has been overwhelmingly positive, which has helped us to create a robust brand image.

While DSwiss has been focused almost exclusively upon pursuing operations within Asia, we do have plans to expand outward and become a household name across the world. Our strategy to do so going forward is by forming partnerships with local companies in various countries that may be willing to stock our products or promote them to their own customers. We believe that by forging strategic relationships and partnerships we can expand our operations across the globe at a greater pace and with greater certainty than we would if we tried to expand on our own.

Results of Operations

Revenues for the year ended December 31, 20182020 and 20172019

The Company generated revenue of $220,119$1,347,718 and $181,398$273,659 for the year ended December 31, 20182020 and 20172019 respectively. Revenue has increased by $38,721$1,074,059 which is a 21.35%392.48% increase comparatively. The revenue mainly represented the supplies of beauty products to the customers. We contribute our increase in revenue towards the success in local and oversea marketing effort.

Cost of Revenue and Gross Margin

Cost of revenue for the Company year ended December 31, 20182020 amounted to $178,287$980,243 as compared to $36,030$181,925 for the year ended December 31, 2017.2019. Increase of $142,257$798,318 in cost of revenue was contributed by increasing packing material cost and product purchase price. As a result, the gross profit has decreasedincreased from $145,368$91,734 for the year ended December 31, 20172019 to $41,832$367,475 for the year ended December 31, 2018,2020, while the gross margin of the Company decreased from 80.14%33.52% in year ended December 31, 20172019 to 19.00%27.27% in year ended December 31, 2018,2020, which is a net increase of decrease of 61.14%6.25%.

Operating Expenses

Selling, general and distributionadministrative expenses for the year ended December 31, 20182020 and 20172019 amounted to $20,579$287,995 and $60,368$242,157 respectively, the increase of $47,860 which is 19.76% higher comparatively which was contributed by the increase of group operations.

Operating expenses for the year ended December 31, 2020 and 2019 amounted to $1,216 and $94,769 respectively, the decrease of $39,788$93,553 which is 65.91%98.72% lower comparatively, such decrease was associated with the Company stringent cost control.

Administrative expenses for the year ended December 31, 2018 and 2017 amounted to $216,074 and $144,181 respectively, the increase of $71,893 which is 49.86% higher comparatively, which was contributed by the increase of office rental. The Company upgraded their Headquarter office from size 711 square feet to 3,500 square feet during August 2018.

Operating expenses for the year ended December 31, 2018 and 2017 amounted to $138,137 and $166,552 respectively, the decrease of $28,415 which is 17.06% lower comparatively, such decrease was associated with the Company stringent cost control.

Other operating expenses for the year ended December 31, 20182020 and 20172019 amounted to $46,445$18,651 and $60,125$56,315 respectively, the decrease of $13,68037,664 which is 22.75%66.88% lower comparatively, such decreaseexpense was associated with the Company stringent cost control.depreciation of fixed assets.

Other Income

TheThe Company recorded an amount of $8,058$104,976 and $966$63,592 as other income for the year ended December 31, 20182020 and 20172019 respectively. This income is derived from the interest income earned through the time deposits placed with banks.and exchange gain.

Net Profit/Loss and Net Profit/Loss Margin

The net profit for the year was 30,045 for the year ended December 31, 2020. The net loss for the year was $371,345295,463 for the year ended December 31, 2018 as compared2019. The increase in net profit of $325,508 which is a 110.17% higher comparatively due to $284,892higher contribution on revenue and stringent cost control. Taking into the profit for the year ended December 31, 2017. The increase in net loss of $86,453 which is a 30.35% higher comparatively. Such decline can be contributed to the substantial decrease in gross income. Taking into the loss for the year ended December 31, 2018,2020, the accumulated loss for the Company has increaseddecreased from $853,637$1,490,845 to $1,218,833.$1,483,170.

Liquidity and Capital Resources

As of December 31, 2018,2020, we had working capital surplusdeficit of $146,423$142,357 consisting of cash and cash equivalent of $188,754$158,004 as compared to working capital deficit of $ 532, 537$182,311 and our cash and cash equivalent of $498,516$48,353 as of December 31, 2017.2019.

Net cash used ingenerated from operating activities for the year ended December 31, 20182020 was $250,464$58,913 as compared to net cash used in operating activities of $345,596$179,671 for the year ended December 31, 2017.2019. The cash used ingenerated from operating activities are mainly for filing fees, professional fees,from prepayments, deposits, and business operation expenses.other receivables.

Net cash used in investing activitiesactivity for the year ended December 31, 20182020 was 64,930$2,045 as compared to net cash ofused in investing activitiesactivity for the year ended, 20172019 were $1,986.$2,082. The cash used in investing activities are mainly for purchase of plant & equipment, and registered trademark.equipment.

Net cash provided by financing activities for the year ended December 31, 20182020 was $42,097$105,143 as compared to $16,251net cash provided by financing activities $78,475 for the year ended December 31, 2017.2019. The net cash provided by financing activities is proceedswere the advances from hire purchase creditor.a director.

The revenues generated from our current business operations alone may not be sufficient to fund our operations or planned growth. We will likely require additional capital to continue to operate our business, and to further expand our business. Sources of additional capital through various financing transactions or arrangements with third parties may include equity or debt financing, bank loans or revolving credit facilities. We may not be successful in locating suitable financing transactions in the time period required or at all, and we may not obtain the capital we require by other means. Our inability to raise additional funds when required may have a negative impact on our operations, business development and financial results.

Critical Accounting Policies and Estimates

Leases

The company determines if an arrangement is a lease at inception. Operating leases are included in operating in operating lease right-of-use (“ROU”) as assets, operating lease non-current liabilities, and operating lease current liabilities in our consolidated balance sheet. Finance leases are property and equipment, other current liabilities, and other non-current liabilities in the consolidated balance sheet.

ROU assets represent the right to use an asset for the lease term and lease liability represent the obligation to make lease payment arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over lease term. As most of the leases doesn’t provide an implicit rate. The company generally use the incremental borrowing rate on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The operating ROU asset also includes any lease payments made and exclude lease incentives. Lease expense for lease payment is recognized on a straight -line basis over lease term. The Company adopted Public Bank Berhad’s base rate lending rate as a reference for discount rate.

Finance leases

Leases that transfer substantially all the rewards and risks of ownership to the lessee, other than legal title, are accounted for as finance leases. Substantially all of the risks or benefits of ownership are deemed to have been transferred if any one of the four criteria is met: (i) transfer of ownership to the lessee at the end of the lease term, (ii) the lease containing a bargain purchase option, (iii) the lease term exceeding 75% of the estimated economic life of the leased asset, (iv) the present value of the minimum lease payments exceeding 90% of the fair value. At the inception of a finance lease, the Company as the lessee records an asset and an obligation at an amount equal to the present value of the minimum lease payments. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company. The periodic rent payments made during the lease term are allocated between a reduction in the obligation and interest element using the effective interest method in accordance with the provisions of ASC Topic 835-30, “Imputation of Interest”.

Use of estimates

In preparing these consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets, and revenues and expenses during the periods reported. Actual results may differ from these estimates.

Cash and cash equivalents

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

Revenue recognition

In accordance with the Accounting Standard Codification Topic 605 “Revenue Recognition” (“ASC 605”), the Company recognizes revenue when the following four criteria are met: (1) delivery has occurred or services rendered; (2) persuasive evidence of an arrangement exists; (3) there are no continuing obligations to the customer; and (4) the collection of related accounts receivable is probable.

Revenue is measured at the fair value of the consideration received or receivable, net of discounts and taxes applicable to the revenue.

Revenue from supplies of beauty products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded. Based on limited operating history, management estimates that there was no sale return for the period reported.

Cost of revenues

Cost of revenues includes the purchase cost of retail goods for re-sale to customers and the packing materials (such as boxes). It excludes purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and other costs of distribution network in cost of revenues.

Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping and handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

Shipping and handling fees are expensed as incurred for the year ended December 31, 20182020 were $2,983,$3,956 while for the year ended December 31, 20172019 were $4,601.$2,214.

Selling, general and administrative expenses

Selling, general and administrative expenses are primarily comprised of travelling and accommodation fees such as petrol, toll and parking and shipping and handling fees.

Cash and cash equivalents

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

Inventories

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income.

Property and equipment

Property and equipment are stated at cost less accumulated depreciation and impairment. Depreciation of plant, equipment and software are calculated on the straight-line method over their estimated useful lives or lease terms generally as follows:

Intangible assets

Intangible assets are stated at cost less accumulated amortization. Intangible assets represented the registration costs of trademarks in Malaysia and Hong Kong which are amortized on a straight-line basis over a useful life of ten years.

The Company follows ASC Topic 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. There were no impairment losses recorded on intangible assets for the year ended December 31, 2018.2020.

Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.

The Company conducts major businesses in Malaysia, Thailand, Hong Kong and China. The Company is subject to tax in these jurisdictions. As a result of its business activities, the Company will file tax returns that are subject to examination by the foreign tax authority.

The Company did not have any unrecognized tax positions or benefits and there was no effect on the financial conditions or results of operations for the year ended December 31, 20182020 and year ended December 31, 2017.2019. The Company and its subsidiary are subject to local and various foreign tax jurisdictions. The Company’s tax returns remain open subject to examination by major tax jurisdictions.

Net lossprofit per share

The Company calculates net lossprofit per share in accordance with ASC Topic 260 “Earnings per share”. Basic lossprofit per share is computed by dividing the net lossprofit by the weighted average number of common shares outstanding during the period. Diluted lossprofit per share is computed similar to basic lossprofit per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive IncomeIncome.

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the Company’s subsidiaries and VIEs in Malaysia, Hong Kong, China and Thailand maintains their books and record in their local currency, Ringgits Malaysia (“MYR”), Hong Kong Dollars (“HK$”), and Chinese Renminbi (“RMB”) and Thai Baht (“THB”) respectively, which is functional currency as being the primary currency of the economic environment in which the entity operates.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity.

Translation of amounts from MYR into US$1, HK$ into US$1 RMB into US$1 and THBRMB into US$1 has been made at the following exchange rates for the respective periods:

Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Fair value of financial instruments:

The carrying value of the Company’s financial instruments: cash and cash equivalents, accounts payable and accrued liabilities, and amount due to a director approximate at their fair values because of the short-term nature of these financial instruments.

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

Fair value estimates are made at a specific point in time based on relevant market information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Recent accounting pronouncements

FASB issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. On June 10, 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915) Elimination of Certain Financial Reporting Requirements, including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation, which eliminates the concept of a development stage entity (DSE) entirely from current accounting guidance. The Company has elected adoption of this standard, which eliminates the designation of DSEs and the requirement to disclose results of operations and cash flows since inception.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. In August 2015, the FASB issued an Accounting Standards Update to defer by one year the effective dates of its new revenue recognition standard until annual reporting periods beginning after December 15, 2017 (2018 for calendar-year public entities) and interim periods therein. Management is currently assessing the impact of the adoption of ASU 2014-09 and has not determined the effect of the standard on our ongoing financial reporting.

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required recognize the following for all leases (with the exception of short-term leases) at the commencement date: 1) A lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and 2) A right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new lease guidance simplified the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company is evaluating this ASU and has not determined the effect of this standard on its ongoing financial reporting.

In September 2017, the FASB has issued ASU No. 2017-13,Revenue Recognition(Topic 605),Revenue from Contracts with Customers(Topic 606),Leases(Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. Both of the below entities may still adopt using the public company adoption guidance in the related ASUs, as amended. The effective date is the same as the effective date and transition requirements for the amendments for ASU 2014-09 and ASU 2016-02.

In January 2017, the FASB issued ASU No. 2017-01 , “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This amendment was effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU No. 2017-01 did not have a material impact on the Company’s financial position, results of operations and liquidity.

In September 2017, the FASB has issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. Both of the below entities may still adopt using the public company adoption guidance in the related ASUs, as amended. The effective date is the same as the effective date and transition requirements for the amendments for ASU 2014-09 and ASU 2016-02.

In February 2018, the FASB has issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information in financial statement. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company has analyzed the consequences of such adoption and has not determined the effect of this standard on its ongoing financial reporting.

In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

Off-Balance Sheet Arrangements

As of December 31, 2018,2020, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements required by this item are located in PART IV of this Annual Report.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Disclosures Control and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

As of December 31, 2018,2020, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on such evaluation, the Company’s management concluded that, during the period covered by this Report, internal controls and procedures over were not effective. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

Identified Material Weakness

A material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting as of December 31, 2018.2020.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 20182020 based on criteria established in Internal Control—Integrated Framework issued by COSO.

Management’s Remediation Initiatives

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2018.2020.

Changes in internal controls over financial reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this Report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting:

This annual report does not include an attestation report of the Company’s registered independent public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered independent public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Our executive officer’s and director’s and their respective ages as of the date hereof are as follows:

Set forth below is a brief description of the background and business experience of our executive officer and director for the past five years.

Leong Ming Chia - President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer, Director

Mr. Leong achieved an Advanced Diploma of Microelectronics & Physics from TAR College in 2003 as well as a Bachelor’s Degree of Microelectronics & Physics from Campbell University in 2005. In 2007 Mr. Leong joined Tradenex, which is a subsidiary of the Federation of Malaysian Manufacturers, as part of their sales and marketing department. Mr Leong was responsible for developing a marketing plan, overseeing the execution and evaluating the results across B2B, B2C and retail sales channels in order to enable inter-enterprise connectivity, communication and collaboration along the business value chain. From March 2009 onward Mr. Leong was appointed as a committee member of Cross Border Business Association in Hong Kong, promoting cross border trade and opportunities. Since January 2012 Mr. Leong joined DSwiss Sdn Bhd as a Business Development Advisor where Mr Leong developed a set of marketing tool and is bringing the company from traditional sales model to e-commerce model. In September 2015, Mr. Leong was also appointed as the chief executive officer and director of the Company.

On May 31, 2017, upon the resignation of Mr. Chua Lee Yee resignation as a Chief Financial Officer, Secretary, Treasurer and Director, Mr. Leong has took over the position as a Chief Financial Officer, Secretary and treasurer along with existing position as the Chief Executive Officer, President and Director.

Mr. Leong’s experience in the marketing and business development have led the Board of Director to reach the conclusion that he should serve as a Director of the Company.

Wong Sui Ting - Director

Mr. Wong serves as a Director in the Company. Mr. Wong holds a Bachelor of Business (Accounting) from Monash University since year 1995. Also, he is an Associate Member of Malaysia Institute of Accountancy (MIA, Chartered Accountant) since 1999 and CPA Australia since 1998. Mr. Wong co-founded Qinetics Solutions Sdn Bhd in 2000 and acts as Chief Financial Officer since the establishment. He was tasked with overseeing and managing the overall financial affairs and operations of Qinetics, playing an active role in corporate decisions and strategies. In 2011, Mr. Wong co-founded and acts as Chief Executive Officer of Forum Digital Sdn Bhd. His responsibility in the company is to oversee the operation and in charge of business development of the company.

Mr. Wong’s experience in accounting and the financial industry, as well as his knowledge of business development, has led the Board of director to reach the conclusion that he should serve as the director of the Company. On May 31, 2017, Mr. Wong was appointed as the director of the Company.

Corporate Governance

The Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations. The Company has not formally adopted a written code of business conduct and ethics that governs the Company’s employees, officers and Directors as the Company is not required to do so.

In lieu of an Audit Committee, the Company’s Board of Directors, is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope, results and effectiveness of the annual audit of the Company’s financial statements and other services provided by the Company’s independent public accountants. The Board of Directors, the Chief Executive Officer and the Chief Financial Officer of the Company review the Company’s internal accounting controls, practices and policies.

Committees of the Board

Our Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does our Company have a written nominating, compensation or audit committee charter. Our Directors believes that it is not necessary to have such committees, at this time, because the Director(s) can adequately perform the functions of such committees.

Audit Committee Financial Expert

Our Board of Directors has determined that we do not have a board member that qualifies as an “audit committee financial expert” as defined in Item 407(D)(5) of Regulation S-K, nor do we have a Board member that qualifies as “independent” as the term is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(14) of the FINRA Rules.

We believe that our Director(s) are capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Director(s) of our Company does not believe that it is necessary to have an audit committee because management believes that the Board of Directors can adequately perform the functions of an audit committee. In addition, we believe that retaining an independent Director who would qualify as an “audit committee financial expert” would be overly costly and burdensome and is not warranted in our circumstances given the stage of our development and the fact that we have not generated any positive cash flows from operations to date.

Involvement in Certain Legal Proceedings

Our Directors and our Executive officers have not been involved in any of the following events during the past ten years:

Code of Ethics

We have not adopted a formal Code of Ethics. The Board of Directors evaluated the business of the Company and the number of employees and determined that since the business is operated by a small number of persons, general rules of fiduciary duty and federal and state criminal, business conduct and securities laws are adequate ethical guidelines. In the event our operations, employees and/or Directors expand in the future, we may take actions to adopt a formal Code of Ethics.

Shareholder Proposals

Our Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors. The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our President, at the address appearing on the first page of this Information Statement.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information concerning the compensation of our Chief Executive Officer, and the executive officers who served at the end of the period December 31, 2018,2020, for services rendered in all capacities to us.

Summary Compensation Table:

Narrative Disclosure to Summary Compensation Table

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive stock options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of our board of directors from time to time. We have no plans or arrangements in respect of remuneration received or that may be received by our executive officers to compensate such officers in the event of termination of employment (as a result of resignation, retirement, change of control) or a change of responsibilities following a change of control.

Stock Option Grants

We have not granted any stock options to our executive officers since our incorporation.

Compensation of Directors

The table below summarizes all compensation of our directors as of December 31, 2018.2020.